Studies covering combined treatments with xipamide. Results of a long-term antihypertensive treatment.
The antihypertensive active of Xipamide was tested in 23 patients. Xipamide was given in combination with clonidine hydrochloride. The diuretic produced additional reductions in the recumbent blood pressure in 15 patients, and the orthostatic pressure in 19 patients. The antihypertensive action corresponds to those of established diuretics. The same responses were obtained in essential and secondary hypertension. A disadvantage associated with long-term treatment is that of hypokalaemia, which occurs at a dose level of 80 mg Xipamide (double the therapeutic dose). We accordingly recommend a dose of 40 mg, and, as a precaution, regular electrolyte checks. The levels of other side-effects-interference in carbohydrate, lipid, and uric acid metabolism and the rise in blood urea nitrogen are the same as for other diuretics.
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001806:Blood Urea Nitrogen; D002712:Chlorides / Q000097:blood; D003000:Clonidine / Q000008:administration & dosage / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D011188:Potassium / Q000097:blood; D012964:Sodium / Q000097:blood; D013997:Time Factors; D014527:Uric Acid / Q000097:blood; D014988:Xipamide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D001786:Blood Glucose; D002712:Chlorides; D004232:Diuretics; D008055:Lipids; D014527:Uric Acid; D014988:Xipamide; D012964:Sodium; D003000:Clonidine; D011188:Potassium